Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 21, 2026 16:05 ET | Source: AEON Biopharma Inc

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
January 14, 2026 11:40 ET | Source: Click Therapeutics

Ultrahuman and Click Therapeutics partner to launch the world’s first biomarker-driven migraine management tool based on FDA-authorized technology

SAN FRANCISCO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Ultrahuman, a global leader in wearable health technology, today announced a partnership with Click Therapeutics, a leader in prescription digital...
December 19, 2025 18:00 ET | Source: AEON Biopharma Inc

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
December 15, 2025 16:05 ET | Source: AEON Biopharma Inc

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong
December 02, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight

New York, USA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight The migraine therapeutics...
November 20, 2025 08:30 ET | Source: AEON Biopharma Inc

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling
November 14, 2025 08:30 ET | Source: AEON Biopharma Inc

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
November 13, 2025 08:30 ET | Source: AEON Biopharma Inc

AEON Biopharma Reports Positive and Robust Biosimilarity Results: Identical Amino Acid Sequence and Highly Similar Functional Analysis Data

AEON Biopharma Reports Positive and Robust Biosimilarity Results: Identical Amino Acid Sequence and Highly Similar Functional Analysis Data
November 13, 2025 08:30 ET | Source: AEON Biopharma Inc

AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes

AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes
October 01, 2025 08:00 ET | Source: AEON Biopharma Inc

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19